InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
buxmaker Free
06/17/11 12:53 PM
profile icon
deadjim Free
06/15/11 7:32 PM
profile icon
deadjim Free
06/15/11 6:55 PM
profile icon
buxmaker Free
06/15/11 2:44 PM
profile icon
deadjim Free
06/03/11 10:14 PM
profile icon
Welsh_Dragon Free
06/03/11 8:35 PM
profile icon
buxmaker Free
06/03/11 2:48 PM
profile icon
Welsh_Dragon Free
05/31/11 12:16 PM
profile icon
deadjim Free
05/30/11 7:23 PM
profile icon
Welsh_Dragon Free
05/27/11 12:51 PM
profile icon
buxmaker Free
05/27/11 12:47 PM
profile icon
Welsh_Dragon Free
05/27/11 12:42 PM
profile icon
Welsh_Dragon Free
05/27/11 10:27 AM
profile icon
buxmaker Free
05/27/11 10:18 AM
profile icon
Welsh_Dragon Free
05/26/11 4:04 PM
profile icon
Welsh_Dragon Free
05/26/11 4:00 PM
profile icon
buxmaker Free
05/26/11 3:17 PM
profile icon
Welsh_Dragon Free
05/26/11 3:11 PM
profile icon
Welsh_Dragon Free
05/26/11 2:58 PM
profile icon
Welsh_Dragon Free
05/26/11 2:06 PM
profile icon
Welsh_Dragon Free
05/24/11 3:31 PM
profile icon
buxmaker Free
05/24/11 3:24 PM
profile icon
Welsh_Dragon Free
05/24/11 2:44 PM
profile icon
Johnstown Free
05/24/11 1:29 PM
profile icon
Welsh_Dragon Free
05/24/11 1:23 PM
profile icon
Welsh_Dragon Free
05/24/11 11:19 AM
profile icon
Johnstown Free
05/24/11 8:55 AM
profile icon
TheFinalCD PremiumMember
05/24/11 8:30 AM
profile icon
Welsh_Dragon Free
05/23/11 3:58 PM
profile icon
Welsh_Dragon Free
05/23/11 3:57 PM
profile icon
Welsh_Dragon Free
05/23/11 3:54 PM
profile icon
buxmaker Free
05/23/11 2:59 PM
profile icon
Welsh_Dragon Free
05/23/11 12:21 PM
profile icon
Johnstown Free
05/23/11 12:15 PM
profile icon
Welsh_Dragon Free
05/23/11 12:12 PM
profile icon
Johnstown Free
05/23/11 11:57 AM
profile icon
Welsh_Dragon Free
05/23/11 10:32 AM
profile icon
buxmaker Free
05/23/11 10:06 AM
profile icon
hwllo Free
05/23/11 9:56 AM
profile icon
buxmaker Free
05/23/11 9:51 AM
profile icon
Welsh_Dragon Free
05/23/11 12:07 AM
profile icon
Welsh_Dragon Free
05/22/11 11:54 PM
profile icon
hwllo Free
05/22/11 10:43 PM
profile icon
seadrifter Free
05/21/11 5:49 PM
profile icon
seadrifter Free
05/21/11 5:41 PM

Introgen Therapeutics, Inc. (fka INGNQ) RSS Feed

Followers
6
Posters
34
Posts (Today)
0
Posts (Total)
208
Created
01/27/05
Type
Free
Moderators
http://www.introgen.com/ http://finance.yahoo.com/q/ks?s=INGN Introgen Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. The company is developing molecular therapeutics, immunotherapies, vaccines, and nano-particle therapies to treat a range of cancers using tumor suppressors and cytokines. It maintains integrated research, development, manufacturing, clinical, and regulatory departments, as well as operates multiple manufacturing facilities, including a commercial scale cGMP manufacturing facility. Its lead product candidate include ADVEXIN therapy, which combines the p53 tumor suppressor with a non-replicating, non-integrating, and adenoviral delivery system. ADVEXIN therapy is in phase-III clinical trials in patients with advanced recurrent squamous cell carcinoma of the head and neck; phase-II clinical trials in squamous cell carcinoma of the oral cavity; and phase-I/early phase-I clinical trial to prevent precancerous oral lesions from developing into cancerous lesions. The company's product candidates also include INGN 241, which is in phase-I/early phase-II clinical trials in patients with solid tumors; and INGN 225, which uses p53 tumor suppressor to create a molecular immunotherapy for cancer, is in phase-I/II trial in patients with breast cancer. In addition, its product candidates include INGN 234, which is in phase-I clinical trial, for the prevention of oral cancers and the treatment of oral leukoplakia; INGN 401, a nanoparticle vector system to deliver the tumor suppressor FUS-1, which is in pre-clinical studies; INGN 402 that contains the p53 tumor suppressor; INGN 403 that contains the mda-7 tumor suppressor; and INGN 007, a replication-competent viral therapy. Introgen Therapeutics has collaborative agreements with VirRx, Inc.; Colgate-Palmolive Company; and SR Pharma plc. The company was founded in 1993 and is based in Austin, Texas.
Board Info
Posts Today
0
Posts (Total)
208
Posters
34
Moderators
New Post